In this regard, individuals with subjective cognitive decline (SCD) are a convenient target population for research studies on preclinical AD. Consequently, there is an urgent need to develop novel sensitive and specific biomarkers for the early identification of asymptomatic individuals at high risk for developing AD dementia before irreversible damage to the brain has been established and cognitive decline arises. The disappointing results of clinical trials testing drugs against AD indicate that these interventions were implemented too late in the disease course and acting on an earlier stage would increase the chances of success. Most AD cases are diagnosed once cognitive decline is already significant, but it is known that identifying the disease at earlier stages would result in cost savings and health benefits for patients, allowing them to modify their lifestyle, enrol in clinical trials, access programs of cognitive stimulation and social resources and make decisions about their future care. AD is the only disorder among the 10 principal causes of mortality still with no treatment or prevention. Alzheimer’s disease (AD), responsible for 60–70% of all dementia cases, is a neurodegenerative condition that progressively and irreversibly impairs cognition and results in a complete loss of autonomy. In the past few decades, there has been an increase of the global prevalence of dementia that is threatening the sustainability of healthcare systems worldwide. Subtle retinal thickness changes in the macular region are already present in SCD and correlate with Aβ uptake. No retinal measurements were associated to conversion to MCI over 24 months. Fifteen participants were classified as FBB-PET+ at baseline and 22 at v2. Mean age of the sample was 64.72 ± 7.27 years 62.8% were females. We assessed the association of sixteen retinal thickness measurements at baseline with FBB-PET status (+/−) and global standardize uptake value ratio (SUVR) as a continuous measure at v0 and v2 and their predictive value on clinical status change (conversion to mild cognitive impairment (MCI)) at v2. One hundred twenty-nine individuals with SCD enrolled in Fundació ACE Healthy Brain Initiative underwent comprehensive neuropsychological testing, OCT scan of the retina and florbetaben (FBB) positron emission tomography (PET) at baseline (v0) and after 24 months (v2).
![how to login to thebrain 9 beta how to login to thebrain 9 beta](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-018-28334-9/MediaObjects/41598_2018_28334_Fig1_HTML.jpg)
We investigated the association of retinal thickness quantified by OCT with Aβ accumulation and conversion to mild cognitive impairment (MCI) over 24 months in individuals with SCD. There is little data about retinal changes in preclinical AD and their correlation with amyloid-β (Aβ) uptake. Subjective cognitive decline (SCD) has been proposed as a risk factor for progression to AD.
![how to login to thebrain 9 beta how to login to thebrain 9 beta](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-018-26863-x/MediaObjects/41598_2018_26863_Fig5_HTML.jpg)
![how to login to thebrain 9 beta how to login to thebrain 9 beta](http://www.twohorsetack.com/images/product/large/143_6_.jpg)
![how to login to thebrain 9 beta how to login to thebrain 9 beta](https://www.mdpi.com/biomedicines/biomedicines-09-00047/article_deploy/html/images/biomedicines-09-00047-g001.png)
Multiple studies show that patients with Alzheimer’s disease (AD) exhibit thinning in several retinal layers compared to age-matched controls. Optical coherence tomography (OCT) of the retina is a fast and easily accessible tool for the quantification of retinal structural measurements. Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain InitiativeĪlzheimer's Research & Therapy volume 12, Article number: 37 ( 2020)